Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT00041730. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Trial of Rituxan(R) Plus FavId(TM) (Tumor-Specific Idiotype-KLH) and GM-CSF Immunotherapy in Patients With Grade 1 or 2 Follicular B-Cell Lymphoma
Study identification
- NCT ID
- NCT00041730
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Favrille
- Industry
- Enrollment
- 90 participants
Conditions and interventions
Conditions
Interventions
- Id-KLH Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2002
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Sep 29, 2009
Started 2002
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Diego | La Jolla | California | 92093 | — |
| Tower Hematology Oncology Medical Group | Los Angeles | California | 90048 | — |
| Oncology Associates of San Diego | San Diego | California | 92123 | — |
| University California, San Francisco | San Francisco | California | 94143 | — |
| University of Florida, Jacksonville | Jacksonville | Florida | 32209 | — |
| H. Lee Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Ochsner Clinical Foundation | New Orleans | Louisiana | 70121 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| New York Medical College - Our Lady of Mercy Medical Center, Comprehensive Cancer Center | The Bronx | New York | 10466 | — |
| Oncology/Hematology Care Clinical Cancer Institute | Cincinnati | Ohio | 45219 | — |
| University Hospitals of Cleveland Case Western, Ireland Cancer Center | Cleveland | Ohio | 44106 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| The Sarah Cannon Cancer Center | Nashville | Tennessee | 37203 | — |
| University of Virginia | Charlottesville | Virginia | 22902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00041730, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2009 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00041730 live on ClinicalTrials.gov.